Atypical Bronchial Carcinoid: Different Therapeutical Approachs Abstract #1203

Introduction: Choosing an adequate treatment for atypical bronchial carcinoid can improve quality of life and survival.
Aim(s): We present 2 examples of different therapeutic decisions in metastatic disease.
Materials and methods: 74 years old patient was diagnosed with a right pulmonar nodule as well as ipsilateral hiliar lymphadenopathy, liver and disseminated bone metastases. Histology demostrated a Ki67:12%. Two years after diagnosis the patient underwent chemotherapy with Everolimus. Afterwards, Peptide Receptor Radionuclide Therapy (PRRT) with 90Yttrium-DOTATOC was started, achieving a disease stabilisation. Therapy control was performed with 68GaDOTATOC PET-CT showing no significant changes. An additional 18FFDG PET was negative. At present the patient is treated by octeotride therapy. 20 years old patient with atypical bronchial carcinoid in the left lung showed a Ki67:3%. Initially he underwent surgery with lobectomy and local lymphadenectomy. Two years later 68GaDOTATOC PET-CT controls demonstrated diseminated liver metastases. A stabilisation was finally achieved with octreotide.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Non digestive NETs (bronchial, MTC, pheochromocytoma)
Presenting Author: Llanos Geraldo Roig
Authors: Geraldo Roig L

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2694 The Incidence of Gastrointestinal Neuroendocrine Tumors in the Russian Population
Introduction: Over the past four decades, the incidence of neuroendocrine tumors (NETs) has increased. The limited choice of treatments, broad clinical variability of the syndrome explains the increased interest in NETs.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Alina Isiangulova
#2695 Different Treatment Options for Patients with Advanced Gastrointestinal Neuroendocrine Tumors
Introduction: Low sensitivity to chemotherapy leaves open question of optimal approach to drug therapy of neuroendocrine tumors (NETs). Somatostatin analogues (SSA) (octreotide, lanreotide) and mTOR inhibitors are successfully used in treatment.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Targeted therapies
Presenting Author: Alina Isiangulova
#2703 Carcinoid Heart Disease: A Retrospective Study and a Multidisciplinary Proposal of a New Algorithm
Introduction: Development of carcinoid heart disease (CHD) is the major negative prognostic factor in patients with the carcinoid syndrome. The only effective treatment is valve replacement. However, the selection of candidates and determination of optimal timing remain unclear. Considerable variability in local treatment strategies exist
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Aicha Bengueddach
#2723 Achieving Objective Response in Treatment of Non-Resectable Neuroendocrine Tumors Does Not Predict Longer Time to Progression Compared to Achieving Stable Disease
Introduction: There are several treatment modalities for unresectable neuroendocrine tumors. Traditionally the goal of these treatments are to reduce the tumor load; objective response (OR). Less emphasis has been put on inducing the tumors to stop growing without reduction in total tumor load; stable disease (SD).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - others, not specified
Presenting Author: MD Espen Thiis-Evensen
Authors: Thiis-Evensen E, Sponheim J, ...
#2731 177Lu-DOTATATE Plus 166Ho-Radioembolization in Patients with Neuroendocrine Tumours; A Single Center, Prospective, Interventional, Non-Comparative, Open Label, Phase II Study (HEPAR PLuS Study)
Introduction: The liver is the most commonly affected organ in metastatic neuroendocrine disease and is the most incriminating factor for patient survival. Additional treatment of liver disease with radioembolization may improve outcome in NET patients with bulky residual liver disease after PRRT.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: M.D. Ph.D. Arthur Braat
Authors: Braat A, Rutger B, Van Rooij R, Braat M, ...